Search hospitals

>

Colorado

>

Greeley

North Colorado Medical Center

Claim this profile

Greeley, Colorado 80631

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

Conducts research for Melanoma

313 reported clinical trials

10 medical researchers

Photo of North Colorado Medical Center in GreeleyPhoto of North Colorado Medical Center in Greeley

Summary

North Colorado Medical Center is a medical facility located in Greeley, Colorado. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Melanoma and other specialties. North Colorado Medical Center is involved with conducting 313 clinical trials across 394 conditions. There are 10 research doctors associated with this hospital, such as Nicholas DiBella, Eric Anderson, Supriya Jain, and Robin A. Lacour, MD.

Area of expertise

1

Breast Cancer

Global Leader

North Colorado Medical Center has run 61 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
Stage IV
2

Lung Cancer

Global Leader

North Colorado Medical Center has run 49 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at North Colorado Medical Center

Lung Cancer

Uterine Cancer

Prostate Cancer

Melanoma

Breast Cancer

Small Cell Lung Cancer

Lymphoma

Bladder Cancer

Oropharyngeal Carcinoma

Cutaneous Melanoma

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at North Colorado Medical Center?

Where is North Colorado Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does North Colorado Medical Center accept?

What awards or recognition has North Colorado Medical Center received?